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ABSTRACT
Prions are pathogenic molecules which cause prion proteins, found abundantly in the
brain, to fold improperly. In the following review, I will discuss the source of prions and
the fundamental biochemical pathways which cause the prion proteins to misfold. I will
also elucidate the factors that determine which form of disease the prions differentiate
into. Prion diseases include Creutzfeldt-Jakob Disease, Bovine Spongiform
Encephalopathy, and Fatal Familial Insomnia. This discussion will also analyze various
benchmarks in brain atrophy and symptoms by which the progression can be
judged. The survival rate of prion diseases is zero percent, and current treatments only
temporarily hinder the afflictions. Finding a pharmacologic or immunotherapeutic
solution to prion replication would drastically increase quality of life for infected patients.

KEYWORDS: Prion disease, treatment, postmortem tonsil biopsy, pathogenic, bovine
spongiform encephalopathy

INTRODUCTION
The prion protein (PrP), an abundant protein in the brains of animals and humans, resides
in the body as a benign molecule whose purpose is thought to be a nerve protector. 1
Prion proteins, however, can become distorted (PrPSc) and have disastrous effects on
the body.2 Prions are infectious pathogens that cause normal prion proteins to misfold
and thereby incite neurodegeneration.1-2 This neurodegeneration is difficult to combat
because it manifests itself in diseases that are highly dissimilar to viruses and bacteria. 1
Among these prion diseases are Creutzfeldt-Jakob disease, Kuru, and bovine spongiform
encephalopathy (commonly known as Mad Cow Disease). 2 These diseases, some of
which are zoonotic, all cause atrophy of the brain that leads to death. 1-2
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Although they are not particularly common, prion diseases are a crucial subject to
science because they represent the deadliest set of diseases on the planet, with a 100
percent fatality rate.2 A cure to these diseases would prevent further psychological
damage and drastically increase survival rate among infected patients. However, little
knowledge exists on the purpose of prion proteins; more research is required to
determine why they exist and what they do. This review will discuss the primary cause
of prion diseases, disease symptoms and progression, and treatments and current
research.

CAUSE OF PRION
Infectious prion proteins stem from abnormal isoforms of the normal prion protein found
in the brains of animals and humans.1 Biochemically, prions cause a point mutation in the
genes of PrP which prevents them from folding properly—these infected proteins cannot
be broken down and accumulate in the brain.2 The point mutation was found via
comparing the sequences of healthy and infected prion proteins. 3 It is unknown how
exactly prions cause the point mutation, but the substituted nucleotide on the C-terminal
end prevents proper folding.4-5 A study conducted on mice in 2016 found the exact
nucleotides affected in PrP genes, along with where prions concentrate in the brain. 3
Mice were infected with prions and the disease phenotype was associated with a
particular region of the gene.3 It was found that the codon 129 genotype distinguished
between Creutzfeldt Jakob Disease (valine substitution) and Fatal Familial Insomnia
(methionine substitution).3 The study also indicated that misfolded prion proteins
disrupt the activities of essential ion channels in the brain—a primary cause of death. 3
The voltage-gated calcium channels within plasma membranes were blocked, leading to
inhibited neurotransmission and muscle control.3 All prion diseases are caused by the
same PrP, but the codon 129 genotype and secretory transport interference dictate the
disease subtype and symptom severity.
Another important concept is distinguishing between causes of different prion disease
strains. All types of prion diseases can be either genetic or spontaneous, both similar in
that they require the codon 129 mutation.4 A study investigated the cerebrospinal fluid
(CSF) of postmortem subjects to determine whether CSF characteristics could predict
disease subtype.6 In sporadic CJD, patients exhibited higher protein accumulation and
rate of health decline.6 In genetic forms, however, the PrP conversion was not as strong
or rapid.6 In other words, sporadic prion diseases demonstrated much faster symptom
progression than genetic (hereditary) prion diseases.
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DISEASES
Infectious prion proteins stem from abnormal isoforms of the normal prion protein found
in the brains of animals and humans.1 Biochemically, prions cause a point mutation in the
genes of PrP which prevents them from folding properly—these infected proteins cannot
be broken down and accumulate in the brain.2 The point mutation was found via
comparing the sequences of healthy and infected prion proteins. 3 It is unknown how
exactly prions cause the point mutation, but the substituted nucleotide on the C-terminal
end prevents proper folding.4-5 A study conducted on mice in 2016 found the exact
nucleotides affected in PrP genes, along with where prions concentrate in the brain. 3
Mice were infected with prions and the disease phenotype was associated with a
particular region of the gene.3 It was found that the codon 129 genotype distinguished
between Creutzfeldt Jakob Disease (valine substitution) and Fatal Familial Insomnia
(methionine substitution).3 The study also indicated that misfolded prion proteins
disrupt the activities of essential ion channels in the brain—a primary cause of death. 3
The voltage-gated calcium channels within plasma membranes were blocked, leading to
inhibited neurotransmission and muscle control.3 All prion diseases are caused by the
same PrP, but the codon 129 genotype and secretory transport interference dictate the
disease subtype and symptom severity.
Another important concept is distinguishing between causes of different prion disease
strains. All types of prion diseases can be either genetic or spontaneous, both similar in
that they require the codon 129 mutation.4 A study investigated the cerebrospinal fluid
(CSF) of postmortem subjects to determine whether CSF characteristics could predict
disease subtype.6 In sporadic CJD, patients exhibited higher protein accumulation and
rate of health decline.6 In genetic forms, however, the PrP conversion was not as strong
or rapid.6 In other words, sporadic prion diseases demonstrated much faster symptom
progression than genetic (hereditary) prion diseases.

SYMPTOMS AND PROGRESSION OF PRION DISEASES
Prion diseases are heterogenous and neurodegenerative, leading to brain atrophy over
time.2 CJD, bovine spongiform encephalopathy, and Kuru all lead to physical afflictions
initially such as muscle stiffness, difficulty walking, and speech problems (Figure 1). 1-2 In
later stages, mental integrity unravels as the patient experiences rapidly developing
dementia, hallucinations, and confusion (Figure 1).1 While FFI is denoted by severe
sleeping disorders and autonomic system dysfunction, dementia and motor
abnormalities are more evident of CJD.3 To date, no studies have been done to compare
5

the onset of symptoms in spontaneous versus inherited disorders. Behavioral changes
were found to be present in about 80% of all prion disease cases within 100 days of
symptom onset.7 Furthermore, prion disease types differ in symptoms according to
atrophy of particular cerebral regions.1 Researchers conducted a longitudinal voxelbased morphology study to determine whether the degenerative regions corresponded
to a specific clinical assessment.8 Patients’ ability to feed themselves and problemsolving skills decreased with the degeneration of particular brain regions, as indicated by
a prion disease rating scale and neurological exam.8 In addition, there was significant
volume loss in the thalamus and basal ganglia, medulla and pons, hippocampal
formation, and the superior parietal lobules (in that order).
Progression of prion diseases sometimes takes years to manifest in affected
patients. One study analyzed the relationship between PrPC (the host-encoded PrP) and
PrPSc (misfolded prion protein).9 Using mice it was ascertained that PrPC levels are
lowered with a host response, leading to decreased PrPSc. 9 This means that prion
disease progression varies widely depending upon host response. This progression, in
some cases, could last for up to a decade. Early on in the manifestation of prion diseases,
a period was found where the patient was asymptomatic. 10 In 2017, an experiment
involving mice identified the asymptomatic phase of prion diseases. 10 The mRNA in
infected cerebral mouse cells was sequenced and compared with RNA in normal cerebral
mouse cells.10 A gene called Cst7 was expressed in staggering levels in the asymptomatic
infected mice compared to the control group mice.10 Cst7 coded for Cystatin-F, a cysteine
inhibitor that assists in immune regulation.10 This means that Cst7 is a viable biomarker
for detecting prion diseases in recently infected patients.
A prominent issue has been identifying prion diseases early in the disease
progression. An experiment for detecting variants of CJD early on in its manifestation
was tested on necropsy patient tonsils.11 This study took 8 tonsil biopsy samples and
compared the PrP they contained with CJD-infected PrP, and the samples matched. 11 If
this method were to be applied to live patients, prion diseases could be discovered long
before the degenerative symptoms occurred and therefore improve quality of life.

TREATMENTS AND CURRENT RESEARCH ON PRION DISEASES
Prion diseases are the only diseases to exhibit a fatality rate of 100 percent, and there is
no cure for them.1 On average, all forms of prion diseases are lethal within about a year
of the onset of symptoms.1 Although there are no known cures for prion diseases,
scientists are researching methods of stalling their progression and combatting the
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prions themselves. A study used quinacrine and chlorpromazine to determine the prionresistant properties of these pharmaceuticals, which are normally used as antimalarial
and antipsychotic drugs.12 The experiment used effective concentrations (EC50) of 0.3
micromolar to 3 micromolar of these derivatives in infected PrP cells. 12 The experiment
showed that tricyclic compounds containing an aliphatic side chain as a whole can inhibit
prion formation, which makes quinacrine and chlorpromazine viable candidates for prion
disease patients.
Researchers are exploring immunotherapeutic techniques that might inhibit prion
formation altogether. A study examined an antibody immunotherapeutic solution to
prion diseases.13 Human prion proteins were injected into mice that were intolerant to
PrPC, inciting anti-PrP antibody development. 13 The PrPSc levels decreased, despite
high initial PrPSc concentrations.13 Ultimately, mice which underwent continued
antibody treatment lived over 300 days longer than mice who went untreated. 13 These
results signify that antibodies could be used to obstruct disease progression in human
prion disease patients, regardless of the disease stage. Another potential antidote was
identified genetically in 2015 in a Papua New Guinea population. 14 The G127V PrP
mutation (featuring an amino acid substitution) was tested in mice against the most
common prion disease strains.14 On the gene containing G127V, a methionine was
located at codon 129.14 It was completely resistant to Kuru and some forms of
Creutzfeldt-Jakob disease, but still succumbed to a few CJD strains. 14 A method of
harnessing this prion-resistant PrP form would render people invulnerable to specific
prion diseases.
In addition to drugs and immunotherapeutic techniques, natural prion inhibitors are also
being explored. Recombinant prion proteins (rPrP), expressed in bacteria, were tested
in vitro for their effect on prion propagation.15 The prion replication was inhibited, as
infected PrP concentrations only marginally increased with the addition of rPrP (roughly
50 nanomolar).15 The study used only bovine spongiform encephalopathy as a subject,
but further studies could show efficacy for other disease types.

CONCLUSION
Prion proteins are proteins that are commonly found in healthy conformations in the
brains of animals and humans. Prions are infectious molecules that cause PrP to misfold
and obstruct essential ion channels in the brain, leading to prion diseases. 1, 6 The most
common forms of these diseases are Creutzfeldt Jakob Disease, bovine spongiform
encephalopathy, and fatal familial insomnia. Although prion disease symptoms such as
7

muscle stiffness seem harmless initially, they quickly progress into sever dementia and
blindness within just a few months.1-2 Currently, there are only experimental methods of
prolonging the lifespan of infected patients.1 Present research on quinacrine and
chlorpromazine along with anti-PrP antibodies demonstrates auspicious results. 12-13
These drugs effectively stalled the progression of the disease even if they did not cure it,
which is promising for future studies in humans. Further research with these
experiments could yield an antibody that prevents prion formation and replication
entirely, eliminating the disease permanently after it has infiltrated the bloodstream.

Physical Symptoms

Figure 1. Physical and Psychological Symptom Progression of Prion Diseases. A flow
chart of the order and length of typical symptoms is shown over a period of six months.
The physical symptoms, listed above the timeline, begin first with muscle stiffness and
difficulty walking.1 The psychological symptoms, listed below the timeline, start with
hallucinations and confusion.1-2 Symptom severity increases with time and typically ends
with a coma.1

REFERENCES
1. Prusiner, S. B. Molecular biology of prion diseases. Science 1991, 252 (5012),
1515.
2. Puig, B.; Altmeppen, H. C.; Glatzel, M. Misfolding leads the way to unraveling
signaling pathways in the pathophysiology of prion diseases. Prion 2016, 10 (6),
434-443, DOI: 10.1080/19336896.2016.1244593.
3. Chiesa, R.; Restelli, E.; Comerio, L.; Del Gallo, F.; Imeri, L. Transgenic mice
recapitulate the phenotypic heterogeneity of genetic prion diseases without
8

developing prion infectivity: Role of intracellular PrP retention in neurotoxicity.
Prion 2016, 10 (2), 93-102, DOI: 10.1080/19336896.2016.1139276.
4. Brown, D. R. Molecular advances in understanding inherited prion diseases.
Molecular Neurobiology 2002, 25 (3), 287-302, DOI: 10.1385/MN:25:3:287.
5. Choi, J.-K.; Cali, I.; Surewicz, K.; Kong, Q.; Gambetti, P.; Surewicz, W. K.
Amyloid fibrils from the N-terminal prion protein fragment are infectious.
Proceedings of the National Academy of Sciences of the United States of America
2016, 113 (48), 13851-13856, DOI: 10.1073/pnas.1610716113.
6. Cramm, M.; Schmitz, M.; Karch, A.; Zafar, S.; Varges, D.; Mitrova, E.; Schroeder,
B.; Raeber, A.; Kuhn, F.; Zerr, I. Characteristic CSF Prion Seeding Efficiency in
Humans with Prion Diseases. Molecular Neurobiology 2015, 51, 396-405, DOI:
10.1007/s12035-014-8709-6.
7. Thompson, A.; MacKay, A.; Rudge, P.; Lukic, A.; Porter, M.-C.; Lowe, J.;
Collinge, J.; Mead, S. Behavioral and Psychiatric Symptoms in Prion Disease.
American Journal of Psychiatry 2014, 171 (3), 265-274, DOI:
10.1176/appi.ajp.2013.12111460.
8. De Vita, E.; Ridgway, G. R.; White, M. J.; Porter, M.-C.; Caine, D.; Rudge, P.;
Collinge, J.; Yousry, T. A.; Jager, H. R.; Mead, S.; Thornton, J. S.; Hyare, H.
Neuroanatomical correlates of prion disease progression - a 3T longitudinal
voxel-based morphometry study. NeuroImage : Clinical 2017, 13, 89-96, DOI:
10.1016/j.nicl.2016.10.021.
9. Mays, C. E.; Kim, C.; Haldiman, T.; van der Merwe, J.; Lau, A.; Yang, J.; Grams, J.;
Di Bari, M. A.; Nonno, R.; Telling, G. C.; Kong, Q.; Langeveld, J.; McKenzie, D.;
Westaway, D.; Safar, J. G. Prion disease tempo determined by host-dependent
substrate reduction. The Journal of clinical investigation 2014, 124 (2), 847-858,
DOI: 10.1172/JCI72241.
10. Nuvolone, M.; Schmid, N.; Miele, G.; Sorce, S.; Moos, R.; Schori, C.; Beerli, R. R.;
Bauer, M.; Saudan, P.; Dietmeier, K.; Lachmann, I.; Linnebank, M.; Martin, R.;
Kallweit, U.; Kana, V.; Rushing, E. J.; Budka, H.; Aguzzi, A. Cystatin F is a
biomarker of prion pathogenesis in mice. PloS one 2017, 12 (2), e0171923e0171923, DOI: 10.1371/journal.pone.0171923.
11. Hill, A. F.; Butterworth, R. J.; Joiner, S.; Jackson, G.; Rossor, M. N.; Thomas, D.
J.; Frosh, A.; Tolley, N.; Bell, J. E.; Spencer, M.; King, A.; Al-Sarraj, S.; Ironside, J.
W.; Lantos, P. L.; Collinge, J. Investigation of variant Creutzfeldt-Jakob disease
and other human prion diseases with tonsil biopsy samples. The Lancet 1999,
353 (9148), 183-189, DOI: https://doi.org/10.1016/S0140-6736(98)12075-5.
12. Korth, C.; May, B. C. H.; Cohen, F. E.; Prusiner, S. B. Acridine and phenothiazine
derivatives as pharmacotherapeutics for prion disease. Proceedings of the
National Academy of Sciences 2001, 98 (17), 9836.

9

13. White, A. R.; Enever, P.; Tayebi, M.; Mushens, R.; Linehan, J.; Brandner, S.;
Anstee, D.; Collinge, J.; Hawke, S. Monoclonal antibodies inhibit prion
replication and delay the development of prion disease. Nature 2003, 422, 80,
DOI: 10.1038/nature01457
https://www.nature.com/articles/nature01457#supplementary-information.
14. Asante, E. A.; Smidak, M.; Grimshaw, A.; Houghton, R.; Tomlinson, A.; Jeelani,
A.; Jakubcova, T.; Hamdan, S.; Richard-Londt, A.; Linehan, J. M.; Brandner, S.;
Alpers, M.; Whitfield, J.; Mead, S.; Wadsworth, J. D. F.; Collinge, J. A naturally
occurring variant of the human prion protein completely prevents prion disease.
Nature 2015, 522 (7557), 478-481, DOI: 10.1038/nature14510.
15. Workman, R. G.; Maddison, B. C.; Gough, K. C. Ovine recombinant PrP as an
inhibitor of ruminant prion propagation in vitro. Prion 2017, 11 (4), 265-276, DOI:
10.1080/19336896.2017.1342919.

SECONDARY REFERENCES
1. Prusiner, S. B. Molecular biology of prion diseases. Science 1991, 252 (5012), 1515.
2. Puig, B.; Altmeppen, H. C.; Glatzel, M. Misfolding leads the way to unraveling
signaling pathways in the pathophysiology of prion diseases. Prion 2016, 10 (6),
434-443, DOI: 10.1080/19336896.2016.1244593.
4. Brown, D. R. Molecular advances in understanding inherited prion diseases.
Molecular Neurobiology 2002, 25 (3), 287-302, DOI: 10.1385/MN:25:3:287.
7. Thompson, A.; MacKay, A.; Rudge, P.; Lukic, A.; Porter, M.-C.; Lowe, J.; Collinge,
J.; Mead, S. Behavioral and Psychiatric Symptoms in Prion Disease. American
Journal of Psychiatry 2014, 171 (3), 265-274, DOI: 10.1176/appi.ajp.2013.12111460.

Hanlon, H. (2019). Prion Diseases: Causes, Symptoms, and Treatments. D.U. Quark, 3(2).
Retrieved from https://dsc.duq.edu/duquark/vol3/iss2/1
10

